Clinical Research Directory

Inclusion Criteria: * Age ≥18 years * Histologically proven adenocarcinoma of the prostate * Low-risk or intermediate-risk prostate cancer according to NCCN risk categories (low risk: T1c-T2a, Gleason score ≤6, and PSA \<10 µg/L; intermediate risk: T2b-T2c or Gleason score 7 or PSA 10-20 µg/L) * Patients with pT1a/b tumor diagnosis after transurethral resection of the prostate (TURP) * Domain score of 17-25 on the International Index of Erectile Function-5 (IIEF-5) questionnaire * Karnofsky score of 70-100 * Written informed consent Exclusion Criteria: * Use of (neo-)adjuvant androgen deprivation therapy * High-risk prostate cancer according to NCCN risk categories (T3a or Gleason score 8-10 or PSA \>20 µg/L) * Patients with "bulky" iT3 tumor diagnosis * Previous pelvic irradiation or radical prostatectomy * Clinical evidence of metastatic disease * Patients who are unable to undergo MRI * Patients who are incompetent to sign written informed consent